Dosimetric impact of interfraction prostate and seminal vesicle volume changes and rotation: A post-hoc analysis of a phase III randomized trial of MRI-guided versus CT-guided stereotactic body radiotherapyTing Martin, Amar U. Kishan, J. Neylon et al.|Radiotherapy and Oncology|2021Cited by 43
Magnetic resonance imaging-guided versus computed tomography-guided stereotactic body radiotherapy for prostate cancer (MIRAGE): Interim analysis of a phase III randomized trial.Amar U. Kishan, Michael L. Steinberg, James Lamb et al.|Journal of Clinical Oncology|2022Cited by 30
<sup>177</sup> Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II StudyAmar U. Kishan, Jérémie Calais, Michael Lauria et al.|Journal of Clinical Oncology|2025Cited by 24
Time-Driven Activity-Based Costing of CT-Guided vs MR-Guided Prostate SBRTNeil R. Parikh, Amar U. Kishan, Mary Ann Clark et al.|Applied Radiation Oncology|2021Cited by 13
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysisAmar U Kishan, Daniel E Spratt, Yilun Sun et al.|The Lancet|2026Cited by 5